Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acoramidis (Primary)
  • Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
  • Focus Adverse reactions; Registrational
  • Acronyms ATTRibute-CM
  • Sponsors Eidos Therapeutics

Most Recent Events

  • 20 May 2025 According to a BridgeBio Pharma media release, data from this study presented at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), taking place in Belgrade, Serbia from May 17 - 20, 2025.
  • 19 May 2025 According to a BridgeBio Pharma media release, data showing that an early, sustained increase in serum transthyretin (TTR) levels predicted improved survival in ATTRibute-CM published in Journal of the American College of Cardiology (JACC)
  • 19 May 2025 Data showing that an early, sustained increase in serum transthyretin (TTR) levels predicted improved survival in ATTRibute-CM presented in the BridgeBio Pharma Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top